This is a Phase 2a, randomized, double-blind, multi-center, placebo-controlled, parallel-design, 2-arm study. Approximately 36 subjects with IPF will be randomized in a 2:1 ratio for GRI-0621 4.5mg or Placebo. GRI-0621 dose of 4.5mg will be compared with placebo following once daily oral administration for 12 weeks.
Concurrently, a Sub-Study will be conducted, examining the number and activity of NKT cells in BAL, for up to 12 eligible subjects (across various centers).
An early-stage patient variability assessment will be completed when 12 subjects have completed 2 weeks of treatment. Followed by an interim analysis performed when 24 subjects complete 6 weeks of treatment.

开始日期2024-04-24

申办/合作机构

GRI Bio Operations, Inc.

CTRI/2023/11/060308

/ Not yet recruitingN/AIIT

Comparative efficacy of different concentration of topical tazarotene and topical tretinoin in acne vulgaris. - NIL

开始日期2023-12-05

申办/合作机构-

CTRI/2023/10/059038

/ RecruitingN/AIIT

Comparative efficacy of topical methotrexate and topical tazarotene in psoriasis vulgaris - NIL

开始日期2023-10-31

申办/合作机构

Government Medical College

100 项与他扎罗汀相关的临床结果

登录后查看更多信息

100 项与他扎罗汀相关的转化医学

登录后查看更多信息

100 项与他扎罗汀相关的专利（医药）

登录后查看更多信息

642

项与他扎罗汀相关的文献（医药）

2026-02-17·JOURNAL OF VIROLOGY

Retinoids enhance NK effector function against HIV-infected CD4 T cells

Article

作者: Lynch, Rebecca M. ; Lochner, Jonathan S. ; McMahon, Elyse K. ; Bosque, Alberto

ABSTRACT:

Novel approaches to sensitize latently infected cells to apoptosis may provide additional methods to eliminate latent reservoirs. Prior research identified several retinoids as potential drugs that increase the sensitivity of HIV-infected cells to cell death. Retinoids are derivatives of vitamin A that target retinoid receptors causing antiproliferative and proapoptotic activity. Several are FDA-approved or in clinical trials. The aim of this study was to evaluate the ability of vitamin A, three of its natural metabolites, and nine synthetic derivatives to sensitize HIV-infected CD4 T cells to NK natural cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC). From the retinoids tested, alitretinoin, tazarotene acid, and AM80 significantly enhanced NK natural cytotoxicity in the presence of IL-15. Mechanistically, these retinoids increased NK degranulation upon target recognition in an HLA-F/KIR3DS1-dependent manner. Furthermore, these retinoids enhanced ADCC by transcriptionally increasing CD16 expression on NK cells. In conclusion, our study has identified at least three retinoids capable of enhancing NK natural cytotoxicity and ADCC against HIV-infected cells. These or other retinoids could be used to reduce HIV persistent reservoirs.

IMPORTANCE:

This study highlights how retinoids, compounds derived from vitamin A, can help the immune system target HIV-infected cells more effectively. HIV often hides in immune cells, making it difficult to fully eliminate the virus. We found that certain retinoids, including alitretinoin, tazarotene acid, and AM80, improve the function of natural killer (NK) cells—key immune cells that target infected cells. These retinoids boost NK cell activity by increasing their ability to release toxic molecules that kill infected cells and by enhancing their response to antibodies targeting HIV. This makes the infected cells more vulnerable to being eliminated. Since some of these retinoids are already approved for medical use, they could offer a promising way to reduce persistent HIV reservoirs in the body and improve efforts to cure the infection.

2026-02-07·Journal of Drug Targeting

Design, optimisation and in vivo evaluation of tazarotene loaded emulgel formulation for the treatment of acne

Article

作者: Kashaw, Sushil Kumar ; Soni, Vandana ; Singh, Amit Pratap

Acne vulgaris is a common dermatological disorder, with current treatments often limited to poor skin penetration, instability, irritation and suboptimal therapeutic outcomes. There is a pressing need for advanced drug delivery systems that can overcome these limitations and enhance treatment efficacy. This study aimed to develop and optimise a novel tazarotene-loaded emulgel formulation, combining the advantages of emulsions and gels to achieve controlled drug release, improved stability and superior clinical performance in topical acne therapy. The formulation was prepared using the incorporation method and optimised through the Box-Behnken statistical design (BBD). Three independent variables, such as Carbopol 940 (X₁), Span 80 (X₂) and Tween 80 (X₃), were assessed for their effects on drug release (Y₁) and viscosity (Y₂). The optimised formulation exhibited desirable characteristics, including pH: 6.6 ± 0.3, viscosity: 28,945 cPs, spreadability: 6.17 ± 0.02 cm², extrudability: 18 ± 2.49 g/cm² and drug content: 85.46 ± 4.02%. In vitro studies demonstrated 87.59 ± 2.6% drug release over 7 h. A skin irritation test in mice confirmed its dermatological safety, with no signs of erythema or oedema. Anti-acne efficacy, evaluated using a Propionibacterium acnes-induced murine model, revealed complete lesion clearance, outperforming a marketed gel. These findings firmly establish the tazarotene-loaded emulgel as a safe, effective, and superior topical treatment for acne.

2026-02-01·CLINICS IN DERMATOLOGY

Vitamins and the skin: Vitamin A and retinoids in dermatology

Article

作者: Katsambas, Andreas ; Dessinioti, Clio

Vitamin A and analogs are widely used in dermatology, with retinoids being natural and synthetic vitamin A derivatives. Topical retinoids (especially tretinoin and tretinoin precursors) can diminish photoaging and contribute to the thickening and restoration of skin collagen. Retinoids used as therapeutic agents include oral retinoids (eg, isotretinoin, acitretin, alitretinoin, and bexarotene) and topical retinoids (eg, isotretinoin, tretinoin, adapalene, tazarotene, and trifarotene). Although retinoids have traditionally been used for skin disorders of keratinization, such as psoriasis, pityriasis rubra pilaris, Darier disease, and ichthyoses, there is a variety of indications of retinoids for the treatment of skin diseases, including diseases of the pilosebaceous unit such as acne vulgaris, pigmentary disorders such as melasma, or cutaneous malignancies such as cutaneous T-cell lymphoma. Other retinoids with distinct routes of administration (oral or topical) and distinct dosing or safety profiles are recommended for different skin disorders. We discuss the mode of action and indications of retinoids used as pharmacologic agents in dermatology and provide an update on their use, effectiveness, and tolerability.

160

项与他扎罗汀相关的新闻（医药）

2026-04-08

·健康导航中

各种皮肤病的一线用药。

💊 皮肤病一线原研药外用药膏权威指南 Topical Dermatology First-Line Original Brand Drugs Guide 参考来源：AAD · EDF · NICE/BNF · PCDS · JAAD · NEJM · JAMA Dermatology ⚠️ 本文档仅供医学专业人员参考，临床用药请遵循医嘱。原研药以原厂商品标准剂型为准。 📖 关于本指南本文档依据美国皮肤科学会（AAD）、欧洲皮肤病论坛（EDF）、英国NICE/BNF、原发性皮肤病护理学会（PCDS）等国际权威指南，整理出15大类常见皮肤病的一线推荐外用原研药（品牌药）信息，包含药物通用名、原研品牌名、生产商、适应症、用法及证据级别。原研药定义：指首个获得专利并上市销售的品牌药物，含有经严格临床试验验证的活性成分与专利配方，代表该成分的最高研发标准。 📋 目录 · CONTENTS 15大皮肤病类别 · 70+原研药品一特应性皮炎（湿疹）糖皮质激素 · 钙调磷酸酶抑制剂 · PDE4抑制剂二寻常型银屑病维生素D类似物 · 糖皮质激素 · 复方制剂三寻常型痤疮维A酸类 · 过氧化苯甲酰 · 抗生素外用四玫瑰痤疮（酒渣鼻）伊维菌素 · 甲硝唑 · 壬二酸五浅表皮肤真菌感染丙烯胺类 · 唑类抗真菌药六脓疱疮（细菌性感染）莫匹罗星 · 夫西地酸 · 瑞他帕菌素七疥疮 5%氯菊酯乳膏 · 苯甲酸苄酯八单纯疱疹 / 带状疱疹阿昔洛韦 · 喷昔洛韦九白癜风他克莫司软膏 · 鲁索替尼乳膏十脂溢性皮炎酮康唑 · 环吡酮胺 · 他克莫司十一接触性皮炎强效糖皮质激素 · 他克莫司十二扁平苔藓超强效糖皮质激素 · 他克莫司十三瘢痕疙瘩 / 增生性瘢痕糖皮质激素制剂 · 硅凝胶十四银屑病甲他扎罗汀 · 卡泊三醇 · 倍他米松十五糖皮质激素效价分级参考国际标准7级分类 🔬 特应性皮炎（湿疹）Atopic Dermatitis 全球发病率15%~20% · 儿童最常见慢性皮肤病 📌 AAD 2023 & 2025 Guidelines · EDF EuroGuiDerm 2025 · JAAD 2024 特应性皮炎（AD）是以反复发作的瘙痒性湿疹为特征的慢性炎症性皮肤病，病理机制涉及Th2/Th22免疫轴失衡、皮肤屏障缺陷（Filaggrin基因突变）和微生物失调。外用药是轻中度AD的一线治疗。 ▌ 一线外用糖皮质激素（Topical Corticosteroids，TCS）通用名原研品牌生产商效价级别主要适应症 & 用法氢化可的松 1%Hydrocortisone 1% Hytone®(Dermol) Medimetriks / Dermol Ⅶ级（弱效）面部、皮肤褶皱处AD；每日2次，薄涂。婴儿首选。地奈德 0.05%Desonide 0.05% DesOwen®Desowen Galderma Ⅵ级（弱-中）面部及皮肤敏感区AD；每日2次。适合婴幼儿及长期维持。曲安奈德 0.1%Triamcinolone 0.1% Kenalog® Bristol-Myers Squibb Ⅳ级（中效）成人躯干四肢AD；每日2~3次。需限制使用时间（≤2周）。糠酸莫米松 0.1%Mometasone furoate Elocon®Elocom Organon / MSD Ⅳ级（中效）成人及2岁以上躯干四肢AD；每日1次，副作用较少，适合维持治疗。丙酸氟替卡松 0.05%Fluticasone prop. Cutivate® GlaxoSmithKline Ⅳ级（中效）成人及1岁以上儿童；每日1~2次。维持治疗有良好安全记录。卤倍他索丙酸酯 0.05%Halobetasol Ultravate® Sun Pharma Ⅱ级（超强效）成人顽固性AD、苔藓化皮损；每日1~2次，≤2周。 ▌ 钙调磷酸酶抑制剂（Topical Calcineurin Inhibitors，TCI）——免激素替代通用名原研品牌生产商效价级别主要适应症 & 用法他克莫司软膏 0.03%/0.1%Tacrolimus Protopic® Astellas Pharma FDA批准（处方） 2岁以上AD；0.03%用于儿童，0.1%用于成人。每日2次。面部/皱褶首选，无皮肤萎缩风险。吡美莫司乳膏 1%Pimecrolimus Elidel® Galderma FDA批准（处方） 2岁以上轻中度AD；每日2次。温和面部外用，适合长期间歇维持。 ▌ PDE4抑制剂 & JAK抑制剂（新型非激素外用药）通用名原研品牌生产商效价级别主要适应症 & 用法克立硼罗软膏 2%Crisaborole Eucrisa® Pfizer FDA 2016批准 ≥3个月AD；每日2次。温和非激素，适合面部及长期使用。PDE4抑制剂。鲁索替尼乳膏 1.5%Ruxolitinib Opzelura® Incyte FDA 2021批准 12岁以上轻中度AD；每日2次。JAK1/2抑制剂，起效快，证据级别最高。地尔替拉乳膏 0.5%Delgocitinib Corectim® LEO Pharma 日本/欧洲批准成人AD；每日2次。泛JAK抑制剂，在欧洲获批。 💡 AAD 2025阶梯治疗要点 ① 轻度AD → 弱效TCS（地奈德/氢化可的松）+ 高频润肤剂（Moisturizer first）② 中度AD → 中效TCS（糠酸莫米松/丙酸氟替卡松）或TCI（Protopic/Elidel）③ TCS不耐受/面部 → 首选TCI或克立硼罗（Eucrisa）④ 快速缓解需求 → 鲁索替尼（Opzelura，1~2天起效）⑤ 重度AD → 升级生物制剂（度普利尤单抗等） 🧬 寻常型银屑病 Psoriasis Vulgaris 全球发病率2%~3% · 慢性免疫介导炎症 📌 AAD/NPF 2020 Guidelines · NICE TA 2018 · EDF 2022 · PCDS 2024 银屑病是以Th17/IL-23轴过度激活、角质形成细胞异常增殖为特征的慢性炎症性皮肤病。外用治疗是轻中度（BSA<10%）的一线方案。强烈推荐维生素D类似物+糖皮质激素复方制剂。 ▌ 维生素D3类似物（Vitamin D Analogues）通用名原研品牌生产商剂型主要适应症 & 用法卡泊三醇 0.005%Calcipotriol Dovonex®Daivonex Leo Pharma 乳膏/软膏/溶液轻中度银屑病；每日2次。体部皮损首选，不可用于面部及皮肤褶皱。他卡西醇Tacalcitol Curatoderm® Maruho 软膏轻度银屑病；每日1次（睡前）。日本及欧洲广泛使用，刺激性低。钙泊三醇/倍他米松复方Calcipotriol+Betamethasone Taclonex®(美)Enstilar®(欧) Leo Pharma 软膏/泡沫剂 NICE/AAD强烈推荐一线。每日1次，可用于体部及头皮。泡沫剂（Enstilar）渗透性更佳，4周疗程。 ▌ 超强效糖皮质激素单药（Superpotent TCS）通用名原研品牌生产商剂型主要适应症 & 用法丙酸氯倍他索 0.05%Clobetasol propionate Temovate®Dermovate® GSK / Teva 乳膏/软膏/溶液/泡沫顽固性银屑病；每日2次，≤4周。头皮银屑病推荐Clobex®泡沫剂或溶液。氟轻松 0.1%Fluocinolone acetonide Synalar® ICN/Valeant 乳膏/软膏慢性稳定型银屑病；每日2~3次。头皮制剂Derma-Smoothe/FS®可长期使用。哈西奈德 0.1%Halcinonide Halog® Ranbaxy 乳膏/软膏 Ⅱ级效价，增厚皮损；每日2~3次，需间歇使用避免萎缩。 ▌ 维A酸类外用药通用名原研品牌生产商剂型主要适应症 & 用法他扎罗汀 0.045%/0.1%Tazarotene Tazorac®Fabior(泡沫) Almirall / Bausch 乳膏/凝胶/泡沫斑块型银屑病；每晚1次。需防晒，孕妇禁用。可联合TCS协同增效。 🏆 银屑病外用治疗推荐级别（NICE/AAD）【A级推荐】卡泊三醇+倍他米松复方（Taclonex®/Enstilar®）—— 疗效最优、顺应性最佳【A级推荐】单用超强效TCS（氯倍他索/哈西奈德）间歇疗法【B级推荐】他扎罗汀乳膏（联合TCS效果更优）【注意】头皮银屑病：优先选择溶液/泡沫剂型（Clobex® Spray、Enstilar® Foam） 🫧 寻常型痤疮 Acne Vulgaris 全球最常见皮肤病 · 85%青少年受累 📌 AAD 2024 Guidelines (JAAD) · NICE CKS 2024 · BCAP UK 2024 AAD 2024年痤疮指南强烈推荐：过氧化苯甲酰（BPO）、外用维A酸类和外用抗生素为三大核心外用药。所有含抗生素方案须联合BPO以降低耐药风险。 ▌ 维A酸类（Topical Retinoids）—— 痤疮治疗基石通用名原研品牌生产商浓度/剂型适应症 & 用法阿达帕林Adapalene Differin® Galderma 0.1%/0.3% 凝胶/乳膏闭口粉刺/炎症性痤疮；每晚1次。刺激性最低，FDA唯一批准的OTC维A酸外用药。维A酸（全反式）tretinoin Retin-A®Retin-A Micro® Ortho Dermatologics 0.025%~0.1% 乳膏/凝胶粉刺性及炎症性痤疮；每晚1次。皮肤刺激性较高，需缓慢起始剂量。孕妇禁用。他扎罗汀Tazarotene Tazorac® Almirall 0.045%/0.1% 乳膏/凝胶中重度痤疮；每晚1次。对结节性痤疮有效，刺激性高，需防晒。阿达帕林+BPO复方Adapalene+BPO Epiduo®Epiduo Forte® Galderma 0.1%+2.5% / 0.3%+2.5% 凝胶 AAD推荐中度痤疮首选复方。每日1次，联合抗菌+溶粉刺双重机制。 ▌ 过氧化苯甲酰（Benzoyl Peroxide，BPO）通用名原研品牌生产商浓度/剂型适应症 & 用法过氧化苯甲酰 2.5%~10%Benzoyl Peroxide Brevoxyl®PanOxyl® Stiefel（GSK）/ Chattem 2.5%/5%/10% 洗剂/乳膏/凝胶 AAD A级推荐，粉刺及炎症性痤疮；每日1~2次。可单用或与抗生素联用，无耐药性。 BPO+克林霉素复方BPO+Clindamycin BenzaClin®Duac® Sanofi / Stiefel (GSK) 5%BPO+1%Clindamycin 凝胶中度炎症性痤疮；每日2次（BenzaClin®）或每日1次（Duac®）。强烈推荐联合方案。 BPO+红霉素复方BPO+Erythromycin Benzamycin® Sanofi 5%BPO+3% Ery 凝胶中度炎症性痤疮；每日2次。注意冷藏保存。 ▌ 外用抗生素（需联合BPO，单独使用易耐药）通用名原研品牌生产商浓度/剂型适应症 & 用法克林霉素磷酸酯 1%Clindamycin phosphate Cleocin T®Clindagel® Pfizer / Galderma 1% 溶液/凝胶/洗剂炎症性痤疮；每日1~2次。须联合BPO使用。甲磺酸沙地霉素 1.5%Sarecycline Seysara®(口服)—— Almirall 外用尚无原研（外用克林霉素为常用替代）壬二酸 15%/20%Azelaic acid Finacea®Skinoren® Bayer Dermatology 15% 凝胶 / 20% 乳膏轻中度炎症性痤疮及色素沉着；每日2次。适合妊娠期使用（B类），同时改善痘印。外用氨苯砜 5%/7.5%Dapsone Aczone® Almirall 5%/7.5% 凝胶 FDA批准炎症性痤疮；每日1~2次。适合成人女性，减少炎症后色素沉着。 🌹 玫瑰痤疮（酒渣鼻）Rosacea 好发于白种人 · 面颊潮红 / 炎症性丘疹脓疱 📌 AAD 2019 Guidelines · PCDS 2024 · AAFP 2024 · NRS Treatment Algorithm 通用名原研品牌生产商剂型适应症 & 用法伊维菌素 1%Ivermectin 1% Soolantra® Galderma 乳膏 PCDS一线推荐，丘疹脓疱型玫瑰痤疮；每日1次，3个月疗程。抗蠕形螨机制。壬二酸 15%Azelaic acid 15% Finacea®Skinoren® Bayer 凝胶丘疹脓疱型；每日2次。AAD强烈推荐，可改善红斑，适合妊娠期。甲硝唑 0.75%/1%Metronidazole MetroCream®Rozex®Noritate® Galderma 0.75%乳膏/凝胶；1%乳膏经典一线药，丘疹脓疱型；每日1~2次。维持治疗首选。溴莫尼定酒石酸盐 0.33%Brimonidine tartrate Mirvaso® Galderma 凝胶面部持续红斑（ETR型）；每日1次，按需使用。α2肾上腺素受体激动剂，起效快（30min）。羟甲唑啉 1%Oxymetazoline Rhofade® Allergan/AbbVie 乳膏成人持续性面部红斑；每日1次。FDA 2017批准，收缩皮肤血管，持续约12h。磷酸伊维菌素+甲硝唑复方（院外调配） ——（调配品）复合药房凝胶重度联合治疗参考（非标准原研） 🍄 浅表皮肤真菌感染 Superficial Fungal Infections 体癣 / 足癣 / 甲癣 / 花斑癣 / 念珠菌病 📌 NICE BNF 2024 · AAFP Tinea Guidelines 2025 · Carepatron Clinical Guidelines 2024 通用名原研品牌生产商类别/浓度适应症 & 用法特比萘芬 1%Terbinafine 1% Lamisil®AT Novartis / GSK 烯丙胺类，1% 乳膏 AAFP首选；体癣/足癣/股癣；每日1~2次，疗程1~2周。杀菌作用，疗程最短。克霉唑 1%Clotrimazole 1% Canesten®Lotrimin®AF Bayer / Bayer Consumer 唑类，1% 乳膏/溶液体癣/足癣/念珠菌感染；每日2~3次，2~4周。广谱抗真菌，念珠菌感染首选。咪康唑 2%Miconazole 2% Daktarin®Monistat® Janssen / J&J 唑类，2% 乳膏/散剂念珠菌病/体股癣；每日2次。Daktarin®口腔凝胶用于口腔念珠菌病。酮康唑 2%Ketoconazole 2% Nizoral® Janssen 唑类，2% 乳膏/洗剂花斑癣/脂溢性皮炎；每日1~2次，2~4周。Nizoral洗发水（1%/2%）用于头皮。益康唑 1%Econazole 1% Spectazole®Pevaryl® Ortho/Cilag 唑类，1%乳膏体癣/足癣/念珠菌感染；每日2次，2~4周。卢立康唑 1%Luliconazole 1% Luzu® Onyx Therapeutics 唑类，1%乳膏 FDA 2013批准；趾间型足癣/体股癣；每日1次，1~2周。最新一代唑类，耐药率低。环吡酮胺 0.77%Ciclopirox Loprox®Penlac® Medicis/Sanofi 乳膏/凝胶/甲涂剂体癣/甲真菌病；乳膏每日2次；甲涂剂每周1次。广谱，兼具抗炎作用。阿莫罗芬 0.25%/5%Amorolfine Loceryl® Galderma 甲涂剂5%，乳膏0.25% 甲真菌病；甲涂剂每周1~2次（欧洲一线推荐）。乳膏用于体癣，欧洲广泛使用。 🦠 脓疱疮及细菌性皮肤感染 Impetigo & Bacterial Infections 金黄色葡萄球菌 / A群链球菌为主 📌 NICE BNF 2024 · AAFP 2014 · WHO Essential Medicines List 2023 通用名原研品牌生产商类别适应症 & 用法莫匹罗星 2%Mupirocin 2% Bactroban® GlaxoSmithKline 假单酸类抗生素 NICE/AAD一线推荐；非大疱性脓疱疮；每日3次，5天。鼻腔MRSA去定植（鼻用软膏）。夫西地酸 2%Fusidic acid 2% Fucidin® Leo Pharma 夫西地烷类抗生素脓疱疮/浅表皮肤感染；每日3次，5~7天。欧洲广泛使用，注意耐药监测。瑞他帕菌素软膏 1%Retapamulin 1% Altabax®Altargo® GSK 截短侧耳素类抗生素 FDA 2007批准；非大疱性脓疱疮；每日2次，5天。对MRSA局部有效。奥泽沙星乳膏 1%Ozenoxacin 1% Xepi® Ferrer / Maruho 喹诺酮类 FDA 2017批准；成人及≥2个月婴儿非大疱性脓疱疮；每日2次，5天。无耐药风险。 🦟 疥疮 Scabies 疥螨感染 · 夜间剧痒 · 传染性强 📌 WHO Guidelines 2020 · Queensland Health Scabies Guidelines 2024 · NICE CKS 通用名原研品牌生产商浓度用法 5%氯菊酯乳膏Permethrin 5% Elimite®Acticin® Prestium Pharma / Connetics 5% 乳膏全球一线首选；全身涂抹8~14h后洗去，7~14天后重复1次。安全用于2个月以上婴儿。 1%苯甲酸苄酯乳液Benzyl benzoate Ascabiol® Sanofi 25% 乳液（稀释至10%~12.5%用于儿童）经济替代方案，全身涂抹24h；可重复2~3次。皮肤刺激性较高。 10%/25%硫磺软膏Sulfur ointment 通用名多家厂商 10%~25% 软膏妊娠期/2个月以下婴儿安全替代；连续涂抹3天，价廉易得。 🧫 病毒性皮肤感染 Viral Skin Infections 单纯疱疹 / 带状疱疹 / 尖锐湿疣 📌 CDC STI Guidelines 2021 · AAD Herpes Guidelines · NICE CKS 2024 通用名原研品牌生产商适应症用法阿昔洛韦 5%软膏Acyclovir 5% Zovirax® GlaxoSmithKline 口唇疱疹/生殖器疱疹（辅助）每日5次（每3h），5天。外用效果有限，口服更有效，主要用于局部辅助。喷昔洛韦 1%乳膏Penciclovir 1% Denavir®Vectavir® Novartis / GSK 口唇疱疹（复发型）每2h 1次（日间），4天。FDA批准外用抗病毒药，较阿昔洛韦皮肤渗透更佳。咪喹莫特 5%/3.75%乳膏Imiquimod Aldara®Zyclara® Medicis/3M 尖锐湿疣/浅表基底细胞癌/日光性角化每周3次（5%），或每日1次（3.75%），涂8h后洗去。免疫调节剂，疗程6~16周。鬼臼毒素 0.5%溶液/0.15%乳膏Podophyllotoxin Condylox®Wartec® Prometheus / Stiefel 尖锐湿疣每日2次，连用3天，休4天，最多4个疗程。患者自用方案首选。鬼臼树脂 15%~25%溶液Podophyllin Podocon-25® Paddock Labs 尖锐湿疣（医生施用）诊室内应用，涂后1~4h洗去，每周1次。不可患者自行使用，致畸。 ⬜ 白癜风 Vitiligo 自身免疫性黑素细胞脱失 · 全球1%发病率 📌 Pigmentary Disorders Society Consensus 2024 (CCID) · NEJM 2022 · AAD Guidelines 通用名原研品牌生产商机制适应症 & 用法他克莫司软膏 0.1%Tacrolimus 0.1% Protopic® Astellas Pharma 钙调磷酸酶抑制剂非节段性白癜风一线推荐（CCID 2024）；每日2次。面部/皱褶皮损首选，可联合NB-UVB。吡美莫司乳膏 1%Pimecrolimus 1% Elidel® Galderma 钙调磷酸酶抑制剂活动期白癜风辅助；每日2次。刺激性低，适合面部，疗效略弱于他克莫司。鲁索替尼乳膏 1.5%Ruxolitinib 1.5% Opzelura® Incyte JAK1/2抑制剂 FDA 2022首个批准用于白癜风的外用药（12岁以上）；每日2次。NEJM 2022 Phase III证明有效。糠酸莫米松 0.1%Mometasone furoate Elocon® Organon 中效糖皮质激素活动期白癜风联合治疗；每日1次，间歇疗法。不可长期单药使用。 ⭐ Opzelura® 里程碑意义 Ruxolitinib（鲁索替尼）乳膏是FDA历史上首个批准外用治疗白癜风的新药。NEJM 2022年双盲随机对照试验显示：使用Opzelura® 52周后，30%以上患者面部白斑面积复色≥75%（F-VASI75），远优于安慰剂组（9%）。这是白癜风外用治疗领域的重大突破。 🧴 脂溢性皮炎 Seborrheic Dermatitis 马拉色菌相关 · 头皮/面部T区好发 📌 AAD Guidelines 2015 · PCDS 2024 · NICE CKS 2024 · Cochrane Review 2022 通用名原研品牌生产商剂型用法酮康唑 2%Ketoconazole 2% Nizoral® Janssen 洗发水/乳膏头皮脂溢：Nizoral®洗发水每周2次，4周；面部脂溢：乳膏每日1~2次，4周。一线首选。环吡酮胺 1%Ciclopirox 1% Loprox® Sanofi 洗发水/乳膏/凝胶头皮/面部脂溢；洗发水每周2~3次；凝胶每日2次。抗菌+抗炎双重作用。硫化硒 1%/2.5%Selenium sulfide Selsun®Selsun Blue® Abbott / Chattem 洗发水/洗液头皮脂溢/花斑癣；每周2次，疗程4周。2.5%需处方。他克莫司软膏 0.1%Tacrolimus 0.1% Protopic® Astellas 软膏顽固性面部脂溢（对激素/抗真菌不耐受）；每日2次。去氢可的松+抗真菌复方Desonide+Antifungal Clobex®+Nizoral® 联合联合方案乳膏严重脂溢性皮炎急性期：短期TCS联合抗真菌（2~4周），后维持抗真菌单药。 🧤 接触性皮炎 Contact Dermatitis 刺激性接触性皮炎（ICD）/ 变应性接触性皮炎（ACD） 📌 AAD Guidelines · NICE CKS 2024 · EAACI Contact Dermatitis Guidelines 通用名原研品牌生产商效价适应症 & 用法丙酸氟替卡松 0.05%Fluticasone prop. Cutivate® GSK Ⅳ级中效急性接触性皮炎（中度）；每日1~2次，最多2周。氯倍他索 0.05%Clobetasol prop. Temovate®Dermovate® GSK Ⅱ级超强效严重过敏性接触性皮炎；每日2次，≤2周。顽固皮损首选。他克莫司 0.1%Tacrolimus Protopic® Astellas 非激素慢性接触性皮炎面部皮损；每日2次。避免激素萎缩风险。氧化锌软膏Zinc oxide paste Desitin®Sudocrem® J&J / Forest Labs 屏障保护剂急性期局部保护；不限制，持续涂抹。作为基础屏障修复。 🍃 扁平苔藓 Lichen Planus 自身免疫性T淋巴细胞攻击基底层角质形成细胞 📌 JAMA Dermatology 2025 · UpToDate 2024 · Cochrane Review 通用名原研品牌生产商类型用法氯倍他索 0.05%Clobetasol prop. Temovate®Dermovate® GSK 超强效TCS 皮肤型扁平苔藓一线；每日2次，4~8周，间歇使用。肥厚型可闭塞疗法增效。他克莫司软膏 0.1%Tacrolimus 0.1% Protopic® Astellas 钙调磷酸酶抑制剂口腔/外阴扁平苔藓一线（黏膜型首选）；每日2次。曲安奈德口腔糊剂 0.1%Triamcinolone acetonide Kenalog in Orabase® Bristol-Myers Squibb 中效TCS糊剂口腔扁平苔藓经典用药；每日2~3次涂于患处，不可漱口。丙酸氟替卡松吸入剂（漱口）Fluticasone propionate inhaler Flonase®/Cutivate® GSK 超说明书使用口腔扁平苔藓（漱口液方案）；每日2~4次，不吞咽。Cochrane证据支持。 ⚡ 瘢痕疙瘩 / 增生性瘢痕 Keloids & Hypertrophic Scars 纤维母细胞异常增殖 · 胶原过度沉积 📌 UpToDate 2024 · ISSS Guidelines · Dermatology Reviews 2023 通用名原研品牌生产商剂型用法氟轻松0.025%+醋酸+丙二醇Fluocinolone acetonide tape Cordran®Tape Lannett 含药胶带增生性瘢痕；贴敷12h/天，2~3个月。闭塞疗法增强TCS渗透，ISSS A级推荐。硅凝胶片/凝胶Silicone gel sheet Mepiform®ScarSil®Kelo-cote® Mölnlycke / Alliance / Crawford 贴片/凝胶增生性瘢痕/预防瘢痕；贴敷≥12h/天，3~6个月。一线非药物治疗，证据充分。洋葱提取物+肝素+尿囊素Onion extract gel Contractubex® Merz Pharmaceuticals 凝胶增生性/成熟瘢痕；每日3次按摩涂抹，≥3个月。欧洲广泛使用，辅助软化。肾上腺素纱布（诊室内局注）Triamcinolone 40mg/mL Kenalog® BMS 注射剂（局部注射）瘢痕疙瘩一线（局注，非外涂）；每4~6周1次，总3~6次。外用单独效果有限。 💅 银屑病甲 Nail Psoriasis 指甲点状凹陷 / 甲板增厚 / 油斑征 📌 GRAPPA Guidelines 2021 · NICE 2022 · AAD Nail Psoriasis Guidelines 2023 通用名原研品牌生产商剂型用法他扎罗汀 0.1%Tazarotene 0.1% Tazorac® Almirall 凝胶轻中度银屑病甲一线；每晚1次涂甲板及周围，封包。适合甲板受累。卡泊三醇/倍他米松复方Calcipotriol+Betamethasone Taclonex®Enstilar® Leo Pharma 软膏/泡沫甲周银屑病；每日1次，4~8周。甲周及甲床受累首选。 5-氟尿嘧啶乳膏 1%/5%5-Fluorouracil Efudex®Carac® Valeant/Dermik 乳膏（超说明书）难治性银屑病甲（甲板增厚）；每日2次封包，部分研究证据支持。氯倍他索溶液 0.05%Clobetasol solution Clobex® Galderma 溶液甲周及甲板银屑病；每晚1次，4周。高渗透溶液剂型更易渗入甲板。 📊 外用糖皮质激素（TCS）国际效价分级参考表 WHO / FDA 七级分类标准 📌 WHO Model List · FDA TCS Classification · Cornell Classification System 外用糖皮质激素按血管收缩试验（Ⅰ~Ⅶ级，Ⅰ级最强）或按效价（超强效/强效/中效/弱效）分类。选择时须根据皮损严重程度、部位、患者年龄及疗程综合评估。效价级别代表原研药（品牌名）通用名浓度适用部位 Ⅰ级（超强效） Diprolene® (Schering) 氯倍他索增效酯丙二醇Betamethasone dipropi. 0.05% 厚皮皮损（手掌/足底/苔藓化），≤2周 Ⅱ级（超强效） Temovate®/Dermovate® (GSK) 丙酸氯倍他索Clobetasol propionate 0.05% 成人顽固皮损，≤2周，避免面部 Ⅱ级（超强效） Ultravate® (Sun Pharma) 卤倍他索Halobetasol prop. 0.05% 厚皮损，≤2周 Ⅲ级（强效） Lidex® (Medicis) 氟轻松醋酸酯Fluocinolide 0.05% 非面部皮损，4周内 Ⅳ级（中强效） Elocon® (Organon/MSD) 糠酸莫米松Mometasone furoate 0.1% 成人体部，每日1次，可较长期使用 Ⅳ级（中强效） Cutivate® (GSK) 丙酸氟替卡松Fluticasone prop. 0.005%/0.05% 成人及儿童（≥1岁）体部 Ⅴ级（中效） Westcort® (Westwood) 戊酸氢化可的松Hydrocortisone valerate 0.2% 面部（短期）/一般皮损 Ⅵ级（弱中效） DesOwen® (Galderma) 地奈德Desonide 0.05% 面部/皱褶/儿童，可较长期使用 Ⅶ级（弱效） Hytone® (Medimetriks) 氢化可的松Hydrocortisone 0.5%/1%/2.5% 面部/眼睑/皱褶/婴儿，长期可用用药重要注意事项 & 药物安全警示 ⚠️ 🚫 妊娠用药 A类（最安全）→ B类 → C类 → D类 → X类（禁用）妊娠期安全：氧化锌、硫磺软膏（A/B）；壬二酸（B）；弱效TCS（B）。禁用：维A酸类（X）、他扎罗汀（X）、氟尿嘧啶（X）、鬼臼毒素（X）。 👶 儿童用药面部/皱褶：优先弱效TCS（Ⅵ~Ⅶ级）或TCI（他克莫司0.03%/吡美莫司）。严格限制超强效TCS使用于儿童（<12岁原则上不用Ⅰ~Ⅱ级）。克立硼罗（Eucrisa）适合≥3个月婴儿，安全性好。 ⏱️ TCS使用原则间歇疗法（每周2次维持）优于连续长期使用，降低皮肤萎缩/毛细血管扩张风险。手掌/足底可耐受较长期强效TCS；面部/阴囊仅用弱效，疗程≤2周。大面积使用强效TCS需警惕HPA轴抑制（成人>50g/周，儿童更低）。 💊 抗生素耐药外用抗生素（克林霉素、红霉素）单药使用易诱导痤疮丙酸杆菌耐药。AAD 2024强制推荐：所有外用抗生素方案须联合过氧化苯甲酰（BPO）使用。外用夫西地酸不宜长期单药用于脓疱疮，建议疗程≤7天。 🔬 原研药 vs 仿制药仿制药（Generic）含相同活性成分，但赋形剂（基质）可能不同，影响皮肤渗透、刺激性和疗效。维A酸类（Retin-A Micro微球缓释技术）、TCI（Protopic软膏基质专利）等原研剂型在透皮性上具优势。临床研究通常基于原研药数据，效价分级也以原研品牌为标准。 📚 参考文献 References 1. Drucker AM, et al. "2025 focused update of the AAD guidelines for atopic dermatitis." JAAD, 2025. https://doi.org/10.1016/j.jaad.2025.02.125 2. EuroGuiDerm Guideline on Atopic Eczema (Living Guideline, March 2025). European Dermatology Forum. https://guidelines.edf.one/guidelines/atopic-ezcema 3. Armstrong AW, et al. "Guidelines of care for the management of psoriasis with topical therapy." JAAD, 2021;84(2):432-470. 4. Zaenglein AL, et al. "Guidelines of care for the management of acne vulgaris." JAAD, 2024;90(5):1006.e1-1006.e30. https://doi.org/10.1016/j.jaad.2023.12.048 5. Thiboutot DM, et al. "New insights into the management of acne." JAAD, 2023. AAD Updated Acne Guidelines. 6. Tanghetti E, et al. "First-line acne treatment: efficacy and safety review." Journal for Nurse Practitioners, 2023;19(5). 7. PCDS. "Rosacea Clinical Guidance." Primary Care Dermatology Society, 2024. https://www.pcds.org.uk/clinical-guidance/rosacea 8. Kerob D, et al. "Rosacea: Practical Guidance." PMC, 2024. PMC10821660. Dermatology and Therapy. 9. NICE BNF. "Skin infections — treatment summaries." British National Formulary, 2024. https://bnf.nice.org.uk/treatment-summaries/skin-infections/ 10. Carepatron. "Tinea Infection Treatment Guidelines." Clinical Resource, August 2024. 11. Queensland Health. "Scabies Public Health Management Guideline." 2024. 12. Sarkar R, et al. "Topical Tacrolimus in Vitiligo: Consensus Paper from the Pigmentary Disorders Society." Clinical, Cosmetic and Investigational Dermatology, December 2024. doi:10.2147/CCID.S455602 13. Rosmarin D, et al. "Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo." New England Journal of Medicine, 2022;387:1445-1455. doi:10.1056/NEJMoa2118828 14. JAMA Dermatology. "Hypertrophic Lichen Planus." 2025. doi:10.1001/jamadermatol.2025.2089 15. GRAPPA. "Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Guidelines for Nail Psoriasis." 2021. 16. WHO Model List of Essential Medicines (23rd Edition, 2023). World Health Organization. 17. FDA Drug Approvals Database. Accessed 2025. https://www.accessdata.fda.gov/

2026-04-08

·BioSpace

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation platform and expand strategic presence in a high-growth international market LA JOLLA, CA, April 08, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it has received a Notice of Allowance from the United Arab Emirates Patent Office (UAE) for UAE Patent No. P6000687/2017, titled “ Prevention and Treatment of Inflammatory Conditions .” The allowed claims cover novel type 2 diverse NKT (“dNKT”) cell agonists and related methods and compositions for the prevention and treatment of inflammatory conditions, further expanding GRI Bio’s intellectual property protection for its proprietary immunomodulatory platform. These claims support therapeutic approaches targeting immune pathways implicated in inflammatory, fibrotic and autoimmune diseases and complement the Company’s existing patent portfolio. This allowance further reinforces the Company’s disciplined approach to building a global intellectual property portfolio designed to support long-term exclusivity and strategic optionality. The UAE represents a strategically significant and rapidly expanding healthcare market, serving as a gateway to the broader Middle East and North Africa (MENA) region. By securing patent protection in this region, GRI Bio strengthens its global intellectual property position for its dNKT cell agonist program and enhances its ability to support future regional partnerships, licensing opportunities and long-term commercialization strategies. “This Notice of Allowance reflects the continued execution of our disciplined global IP strategy,” said Marc Hertz, Chief Executive Officer of GRI Bio. “Securing protection in key international markets strengthens our platform and supports the advancement of our pipeline while creating additional opportunities for long-term value for shareholders.” The allowed application supports GRI Bio’s broader platform focused on modulating NKT cell biology, an emerging therapeutic approach designed to regulate immune responses across a range of diseases with significant unmet need. This patent further reinforces the strength and durability of the Company’s growing global intellectual property portfolio. GRI Bio remains focused on advancing its lead program, GRI-0621, while leveraging its growing chemistry platform and library of over 500 proprietary compounds to support future pipeline expansion and potential strategic partnerships. About GRI Bio, Inc. GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of Natural Killer T (“NKT”) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT (“iNKT”) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an RARβγ agonist shown to inhibit the activity of key immune cells, like iNKT cell activity, and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 diverse NKT (“dNKT”) agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline. Investor Contact: JTC Team, LLC Jenene Thomas (908) 824-0775 GRI@jtcir.com

免疫疗法

2026-04-01

·北京老年医院皮科

黄褐斑治疗的最新指南，来了

黄褐斑治疗已从传统 “单纯去色素”转向抗炎、修复屏障、调节血管、抑制黑素、系统维稳的综合精准管理模式。基于 2025 国际黄褐斑共识与 2024-2026 年最新进展，对其相关治疗进展做一科普介绍，希望对大家有帮助。一、核心治疗理念转变（2025 年关键突破）从 “黑素中心论” → 多维度病理模型1、紫外线：持续激活黑素与炎症；2、血管扩张 / 增生：红斑型黄褐斑（简称：红褐斑）；3、皮肤屏障破损：经皮失水高、敏感；4、慢性炎症：IL-1α、TNF-α、干细胞因子升高；5、黑素细胞异常活化：导致黑素小体转运异常治疗原则：先控炎症、修复屏障 → 再淡色素 → 长期维持防复发分型治疗：表皮型 / 真皮型 / 混合型 / 血管型（红斑明显）分期治疗：活动期（色深、易反黑）→药物 / 抗炎为主；稳定期 →联合光电二、外用药物最新进展1. 传统优化：氢醌（HQ）4%：仍为一线，主张间歇、短程（3月左右）；三联乳膏（TCC）：4% 氢醌 + 0.05% 维 A 酸 + 糖皮质激素，疗效最强，但刺激大，国内已获批。2. 非氢醌主流（更安全、适合长期）氨甲环酸（TA）/传明酸：2–5% 外用凝胶 / 精华，抑制黑素 + 收缩血管，尤其适合红褐斑，温和、孕妇可用、不易反黑。壬二酸（AzA）：15–20% 乳膏 / 凝胶，抗炎 + 抑菌 + 选择性抑制异常黑素细胞，孕妇安全，敏感肌友好、无褐黄病风险。烟酰胺： 4%–5%乳膏，减少黑素小体转移、抗炎、修复屏障，常与维 C、维 E、阿魏酸复配。3. 2025–2026 新型外用（临床 / 上市阶段）硫胺醇（Thiamidol）：0.1%–0.2%乳膏，强效酪氨酸酶抑制剂，12 周疗效接近 4% 氢醌，刺激性更低。马拉色菌素（Malassezin）：抑制黑素合成，快速起效、不良反应小。改良维 A 酸类：他扎罗汀 0.1%，脂质体，缓释、刺激小，抑制黑素与炎症。4. 外用复方趋势（精准多通路）TA + 壬二酸 + 烟酰胺：温和抗炎淡斑；维 C 四己基癸醇酯（脂溶性维 C）+ 维 E + 阿魏酸：强效抗氧化；羟丙基四氢吡喃三醇（玻色因）+ 烟酰胺 + 己酰基甘氨酸：修复 + 淡斑三、系统（口服）治疗最新进展1. 一线：氨甲环酸（TA）唯一强推荐口服药方案：250 mg / 次，2 次 / 天，经期停，疗程3–6 个月；机制：抑制纤溶酶→黑素细胞干细胞因子，抑制血管内皮生长因子（VEGF） → 收缩异常血管；禁忌：血栓病史、高凝状态、严重高血压、孕期；常见：月经减少（停药恢复）、轻微胃肠不适。2. 新型口服（2024–2026）低剂量口服维 A 酸（10 mg / 天）：抑制黑素、调节角化、抗炎；需避孕、监测血脂 / 肝功能。（需在皮科医师指导下使用）四、光电 / 物理治疗最新进展（稳定期联合）1. 激光：低能量、光调节、低损伤为原则大光斑低能量调 Q1064（激光调色）：每周 1 次，8–10 次；几乎无停工期；皮秒激光（Pico），532/1064 nm：光机械效应 > 热效应，反黑风险低；非剥脱点阵（1550 nm / 1927 nm）：刺激胶原、修复真皮屏障与基底膜，减少黑素掉入真皮。疗程：4–6 次，间隔 1 个月； 2. 精准光子：血管 + 色素双靶点治疗DPL 窄谱强脉冲光（550–650 nm）：精准封闭血管、击碎色素，对血管型黄褐斑（红 + 褐）最优；方案：每月 1 次，4 次；低能量起始，需耳前测试；IPL 优化：Cut-off 590–615 nm，去短波长、减少热损伤。3. 微针 / 射频微针（联合药物）微针 + 氨甲环酸 / 维 C / 谷胱甘肽导入：促进吸收、效果提升、减少复发。射频微针（黄金微针）：热效应 + 机械损伤，收缩血管、刺激胶原、修复屏障、抑制黑素，适合真皮型 + 松弛 + 红褐斑。4. 化学剥脱（刷酸辅助）20%–50% 果酸（甘醇酸）：每 2 周 1 次，4–6 次，安全、促进药物渗透。复合酸 / 水杨酸：温和抗炎、适合敏感肌。五、生物制剂与靶向治疗（前沿）Janus 激酶（JAK）抑制剂（外用 / 口服）：抑制 JAK-STAT → 炎症因子与黑素激活，但长期安全性待验证、感染风险。干细胞因子（SCF）/c-Kit 抑制剂：阻断黑素细胞活化关键通路，抗 VEGF / 抗血管生成。六、2025 国际共识推荐分级方案（最实用）1. 一线（基础 + 首选）严格防晒：SPF50+ PA++++，每 2 小时补涂 + 硬防晒；修复屏障：外用：2–5% 氨甲环酸或 15–20% 壬二酸或 4% 氢醌（间歇）口服：氨甲环酸 250 mg bid（中重度）2. 二线（一线效果不佳）外用复方：TA + 壬二酸 + 烟酰胺；三联乳膏（间歇）化学剥脱：20%–50% 果酸光电：低能量 Q1064、DPL、非剥脱点阵（稳定期）3. 三线（顽固）微针 + 药物导入、射频微针；JAK 抑制剂外用（临床试验）；口服低剂量维 A 酸（严格监控）。七、长期管理与防复发（关键）防晒终身：紫外线是第一复发诱因。维持治疗：淡斑后每周 2–3 次外用 TA / 壬二酸 / 烟酰胺，每月低能量光子。规避诱因：激素波动（避孕、怀孕、更年期）、熬夜、压力、高热环境（厨房、暴晒）、刺激性护肤品、过度刷酸、激素 / 重金属产品。屏障修复贯穿全程：黄褐斑皮肤普遍屏障受损。

上市批准临床3期临床结果申请上市CSCO会议

100 项与他扎罗汀相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01132	他扎罗汀	D05AX05	DB00799

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
面部皱纹	美国	Almirall LLC	2002-09-30
色素沉着过多	美国	Almirall LLC	2002-09-30
寻常痤疮	美国	AbbVie, Inc.	1997-06-13
寻常痤疮	美国	Almirall LLC	1997-06-13
斑块状银屑病	美国	Almirall LLC	1997-06-13
斑块状银屑病	美国	AbbVie, Inc.	1997-06-13

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
寻常性银屑病	临床3期	中国	-	2010-03-15
特发性肺纤维化	临床2期	美国	GRI Bio Operations, Inc.	2024-04-24
特发性肺纤维化	临床2期	澳大利亚	GRI Bio Operations, Inc.	2024-04-24
特发性肺纤维化	临床2期	英国	GRI Bio Operations, Inc.	2024-04-24
慢性肝病	临床2期	南非	GRI Bio Operations, Inc.	2015-09-01
银屑病关节炎	临床2期	德国	Almirall SA	2014-02-01
甲银屑病	临床2期	德国	Almirall SA	2014-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06331624 (GlobeNewswire) 人工标引	临床2期	特发性肺纤维化 PRO-C3	36	GRI-0621	餘淵築繭鏇鑰鏇願衊築(齋餘網願網淵獵選窪製) = 膚積觸艱襯衊鹹鹽憲艱膚衊網築鑰壓選衊糧廠 (遞醖獵製醖膚膚窪廠膚 )	积极	2025-05-08
				Placebo	-
NCT04071756 (CTgov)	临床2期	实体瘤 \| 结直肠癌 \| 手足综合症	8	Topical Tazarotene (Topical Tazarotene 0.1% Gel Plus BPS)	積觸廠鏇積築衊顧膚鹹 = 繭憲顧築蓋積願膚糧願鹽廠淵選衊夢願選夢鹽 (窪醖遞艱憲壓築獵憲襯, 鬱網鬱範鏇衊壓範襯遞 ~ 選觸膚獵窪簾鏇艱齋淵) 更多	-	2023-11-15
				Placebo (Placebo Gel Plus BPS)	積觸廠鏇積築衊顧膚鹹 = 積網網築襯繭襯範簾選鹽廠淵選衊夢願選夢鹽 (窪醖遞艱憲壓築獵憲襯, 齋夢築壓餘壓繭襯鏇蓋 ~ 淵淵獵齋鑰築鑰積繭鹹) 更多
NCT03168334 (CTgov)	临床3期	寻常痤疮	801	IDP-123 Lotion	淵範鏇願鑰艱獵齋齋廠(壓鹽衊遞餘蓋構製壓鏇) = 繭簾窪壓鹽繭鑰襯憲積鑰繭築衊築鹹廠簾醖淵 (願鑰糧繭觸鹽選顧廠鹽, 15.33) 更多	-	2021-04-01
NCT03168321 (CTgov)	临床3期	寻常痤疮	813	IDP-123 Lotion	範衊鏇糧糧壓繭憲鏇獵(鏇遞衊遞壓網醖鹽繭廠) = 蓋鑰範鏇蓋鬱顧鏇蓋繭顧齋繭窪觸憲網積壓糧 (醖繭衊艱選衊壓窪選壓, 14.72) 更多	-	2021-04-01
NCT05555797 (Pubmed \| Dermatology)	临床4期	斑块状银屑病	-	Tazarotene/betamethasone dipropionate cream	願醖餘齋範膚齋遞鹹膚(壓顧糧觸鬱積鹹衊獵淵) = Adverse reactions occurred in 445 patients (20.8%) at week 4. The most frequently reported adverse reactions were local skin irritation, including pruritus (10%), pain (6.7%), erythema (6.1%) and desquamation (1.8%) 廠醖築蓋繭鹽積憲觸鏇 (顧夢繭獵蓋窪憲鏇糧獵 ) 更多	积极	2020-12-22
NCT03599193 (CTgov)	临床2期	寻常痤疮	58	Tazarotene Lotion, 0.1% (DFD-03 Lotion)	顧餘網獵獵憲構選鹹觸(壓鹽衊襯顧鑰鏇窪蓋夢) = 範鬱遞網鬱夢膚餘積製繭窪襯蓋繭糧鏇壓築醖 (顧鬱壓鬱顧蓋艱獵鏇築, 50.0) 更多	-	2020-09-14
				Tazarotene Cream, 0.1% (Tazorac Cream)	顧餘網獵獵憲構選鹹觸(壓鹽衊襯顧鑰鏇窪蓋夢) = 觸憲選簾範鹽壓願蓋艱繭窪襯蓋繭糧鏇壓築醖 (顧鬱壓鬱顧蓋艱獵鏇築, 40.2) 更多
NCT03292640 (CTgov)	临床3期	寻常痤疮	547	tazarotene (DFD-03 Lotion (0.1% Tazarotene))	鹽糧鹽網觸壓憲淵夢鹹(衊網餘遞鏇餘醖鑰範艱) = 襯窪鏇觸夢衊獵淵觸齋蓋遞願餘顧網齋淵夢網 (餘淵膚醖蓋憲襯積夢獵, 13.82) 更多	-	2020-06-09
				DFD-03 (0% tazarotene) Lotion (Placebo) (DFD-03 Vehicle (0% Tazarotene))	鹽糧鹽網觸壓憲淵夢鹹(衊網餘遞鏇餘醖鑰範艱) = 蓋繭窪窪廠廠築壓觸鹹蓋遞願餘顧網齋淵夢網 (餘淵膚醖蓋憲襯積夢獵, 13.27) 更多
NCT03290027 (DFD-03, CTgov)	临床3期	寻常痤疮	550	DFD-03 (Active)	憲繭範齋範壓願憲鏇襯(夢鑰鑰糧艱窪鑰獵艱醖) = 顧廠蓋衊願網夢鬱糧鏇鏇鹹醖選顧蓋構醖鏇餘 (獵廠廠淵醖壓網積顧遞, 9.81) 更多	-	2020-05-26
				Placebo Comparator (Vehicle)	憲繭範齋範壓願憲鏇襯(夢鑰鑰糧艱窪鑰獵艱醖) = 鬱餘願蓋鏇齋範糧壓顧鏇鹹醖選顧蓋構醖鏇餘 (獵廠廠淵醖壓網積顧遞, 9.13) 更多
NCT02267746 (CTgov)	临床3期	寻常痤疮	893	Vehicle foam	製膚獵顧餘衊積繭夢選(壓齋淵鑰襯夢鏇顧糧遞) = 廠顧餘夢襯壓糧選簾窪夢鹽觸襯簾憲夢淵餘鹽 (蓋襯醖鏇範獵積蓋獵窪, 24.126)	-	2020-05-11
NCT01094717 (CTgov)	N/A	银屑病	13	Sham excimer laser+Acitretin 25Mg Oral Capsule (Acitretin and Sham Excimer Laser)	構簾膚夢襯選膚廠蓋製 = 選簾願襯憲製繭艱鏇網衊築膚鬱製簾糧築鑰壓 (壓衊壓製淵窪艱齋積範, 餘鹽遞衊獵選鑰選蓋壓 ~ 夢醖齋範齋繭艱網範鏇) 更多	-	2019-06-26
				Sham excimer laser+Tazarotene 0.1% Gel,Top (Tazarotene and Sham Excimer Laser)	構簾膚夢襯選膚廠蓋製 = 築夢鹹糧鹽廠簾壓糧鏇衊築膚鬱製簾糧築鑰壓 (壓衊壓製淵窪艱齋積範, 願餘衊鬱襯遞糧構醖夢 ~ 顧膚鏇淵鬱繭構餘齋積) 更多